ORIGINAL PAPER
Twenty-five years of growth hormone treatment
in non-dialyzed children with chronic kidney disease
in Poland – efficacy, safety, metabolic effects,
and factors influencing response
1
Department of Paediatrics and Nephrology, Medical University of Warsaw, Warsaw, Poland
2
Department of Paediatrics and Nephrology, Doctoral School, Medical University of Warsaw, Warsaw, Poland
3
Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland
Submission date: 2022-02-03
Final revision date: 2022-03-30
Acceptance date: 2022-04-11
Publication date: 2022-10-11
Pediatr Pol 2022;97(3):200-212
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Recombinant human growth hormone (rhGH) treatment has been a well-established means of dealing with chronic kidney disease (CKD)-related short-stature for over 25 years. The aim of this study was to evaluate the safety, efficacy, metabolic effects, and factors influencing response to rhGH treatment in Poland.
Material and methods:
156 non-dialyzed children with different stages of CKD were analysed regarding anthropometric features, biochemical parameters, calcium-phosphorus metabolism, bone mineral density (BMD), and CKD progression. The analysis comprised 24 months of treatment.
Results:
The median height velocity during the whole course of treatment in the analysed group was 8 cm/year. In the first year of treatment, it was significantly faster than in the second year (9.5 cm/year and 7.6 cm/year, respectively, p < 0.01) and did not differ between children with CKD stage 2–3 (group A) and with CKD stage 4–5 (group B). Age of therapy onset correlated negatively with total ΔheightSDS (r = –0.21, p < 0.05). Throughout the treatment we observed a decrease of hypercalcemia (both groups) and an increase of hyperphosphatemia (group A). In the first year parathyroid hormone (PTH), IGF-1, CaxP, and ALP increased. In the second year PTH, IGF-1, and CaxP stabilized, and ALP decreased. ΔheightSDS correlated negatively with initial and mean serum cholesterol. Serum triglyceride concentration increased in the course of treatment. After 24 months, total body BMD increased in group A, and lumbar spine BMD increased in both groups (A and B). The mean decrease of glomerular filtration rate was 2.5 ml/min/1.73 m2/year.
Conclusions:
rhGH treatment is safe and effective, and should include the youngest CKD patients. Our results suggest that there might be a relationship between rhGH treatment and lipid profile, which necessitates further research.
Recombinant human growth hormone (rhGH) treatment has been a well-established means of dealing with chronic kidney disease (CKD)-related short-stature for over 25 years. The aim of this study was to evaluate the safety, efficacy, metabolic effects, and factors influencing response to rhGH treatment in Poland.
Material and methods:
156 non-dialyzed children with different stages of CKD were analysed regarding anthropometric features, biochemical parameters, calcium-phosphorus metabolism, bone mineral density (BMD), and CKD progression. The analysis comprised 24 months of treatment.
Results:
The median height velocity during the whole course of treatment in the analysed group was 8 cm/year. In the first year of treatment, it was significantly faster than in the second year (9.5 cm/year and 7.6 cm/year, respectively, p < 0.01) and did not differ between children with CKD stage 2–3 (group A) and with CKD stage 4–5 (group B). Age of therapy onset correlated negatively with total ΔheightSDS (r = –0.21, p < 0.05). Throughout the treatment we observed a decrease of hypercalcemia (both groups) and an increase of hyperphosphatemia (group A). In the first year parathyroid hormone (PTH), IGF-1, CaxP, and ALP increased. In the second year PTH, IGF-1, and CaxP stabilized, and ALP decreased. ΔheightSDS correlated negatively with initial and mean serum cholesterol. Serum triglyceride concentration increased in the course of treatment. After 24 months, total body BMD increased in group A, and lumbar spine BMD increased in both groups (A and B). The mean decrease of glomerular filtration rate was 2.5 ml/min/1.73 m2/year.
Conclusions:
rhGH treatment is safe and effective, and should include the youngest CKD patients. Our results suggest that there might be a relationship between rhGH treatment and lipid profile, which necessitates further research.
REFERENCES (51)
1.
Seikaly MG, Salhab N, Gipson D, et al. Stature in children with chronic kidney disease: analysis of NAPRTCS database. Pediatr Nephrol 2006; 21: 793-799.
2.
Vester U, Schaefer A, Kranz B, et al. Development of growth and body mass index after pediatric renal transplantation. Pediatr Transplant 2005; 9: 445-449.
3.
Cansick J, Waller S, Ridout D, et al. Growth and PTH in prepubertal children on long-term dialysis. Pediatric Nephrol 2007; 22: 1349-1354.
4.
Al-Uzri A, Matheson M, Gipson DS, et al. The impact of short stature on health-related quality of life in children with chronic kidney disease. J Pediatr 2013; 163: 736-741 e1.
5.
Wong CJ, Moxey-Mims M, Jerry-Fluker J, et al. CKiD (CKD in Children) prospective cohort study: a review of current findings. Am J Kidney Dis 2012; 60: 1002-1011.
6.
Furth SL, Abraham AG, Jerry-Fluker J, et al. Metabolic abnormalities, cardiovascular disease risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc Nephrol 2011; 6: 2132-2140.
7.
Koch VH, Lippe BM, Nelson PA, et al. Accelerated growth after recombinant human growth hormone treatment of children with chronic renal failure. J Pediatr 1989; 115: 365-371.
8.
Drube J, Wan M, Bonthuis M, et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol 2019; 15: 577-589.
9.
Program lekowy Ministerstwa Zdrowia – Leczenie niskorosłych dzieci z przewlekłą niewydolnością nerek. Available from: https://www.gov.pl/web/zdrowie....
10.
Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20: 629-637.
11.
Greulich WW. Radiographic atlas of skeletal development of the hand and wrist. 2nd ed. Stanford University Press, Stanford 1959.
12.
Tanner JM, Goldstein H, Whitehouse RH. Standards for children’s height at ages 2-9 years allowing for height of parents. Arch Dis Childhood 1970; 45: 755-762.
13.
European Society for Paediatric Nephrology/European Renal Association – European Dialysis and Transplantation Association Registry. Available from: https://espn-reg.org/index.jsp.
14.
The World Health Organization Child Growth Standards. Available from: https://www.who.int/tools/chil....
15.
Bonthuis M, Jager KJ, Abu-Hanna A, et al. Application of body mass index according to height-age in short and tall children. PLoS One 2013; 8: e72068.
16.
Gao T, Leonard MB, Zemel B, et al. Interpretation of body mass index in children with CKD. Clin J Am Soc Nephrol 2012; 7: 558-564.
17.
Fine RN, Kohaut EC, Brown D, et al. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo- controlled study. J Pediatr 1994; 124: 374-382.
18.
Kari JA, Rees L. Growth hormone for children with chronic renal failure and on dialysis. Pediatr Nephrol 2005; 20: 618-621.
19.
Haffner D, Wühl E, Schaefer F, et al. Factors predictive of the short- and long-term efficacy of growth hormone treatment in prepubertal children with chronic renal failure. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Am Soc Nephrol 1998; 9: 1899-1907.
20.
Hokken-Koelega A, Mulder P, De Jong R, et al. Long-term effects of growth hormone treatment on growth and puberty in patients with chronic renal insufficiency. Pediatr Nephrol 2000; 14: 701-706.
21.
Mehls O, Lindberg A, Nissel R, et al. Predicting the response to growth hormone treatment in short children with chronic kidney disease. J Clin Endocrinol Metab 2010; 95: 686-692.
22.
Fine RN, Kohaut E, Brown D, et al. Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Int 1996; 49: 781-785.
23.
Bérard E, André JL, Guest G, et al. Long-term results of rhGH treatment in children with renal failure: experience of the French Society of Pediatric Nephrology. Pediatr Nephrol 2008; 23: 2031-2038.
24.
Reinehr T, Lindberg A, Koltowska-Haggstrom M, et al. Is growth hormone treatment in children associated with weight gain? – longitudinal analysis of KIGS data. Clin Endocrinol (Oxf) 2014; 81: 721-726.
25.
Adamczuk D, Leszczyńska B, Skrzypczyk P, et al. Twenty years of growth hormone treatment in dialyzed children in Poland – results of national multicenter study. Adv Med Sci 2019; 64: 90-99.
26.
Rees L. Growth hormone therapy in children with CKD after more than two decades of practice. Pediatr Nephrol 2016; 31: 1421-1435.
27.
Jedrzejowski A, Panczyk-Tomaszewska M, Roszkowska-Blaim M, et al. Growth hormone therapy and lipid profile in children on chronic peritoneal dialysis. Pediatr Nephrol 2002; 17: 830-836.
28.
Labarta JI, Arriba Ad, Ferrer M, et al. Growth and metabolic effects of long-term recombinant human growth hormone (rhGH) treatment in short children born small for gestational age: GH-RAST study. J Pediatr Endocrinol Metab 2020; 33: 923-932.
29.
Aurensanz Clemente E, Samper Villagrasa P, Ayerza Casas A, et al. Effects of growth hormone treatment on anthropometrics, metabolic risk, and body composition variables in small for gestational age patients. An Pediatr (Barc) 2017; 86: 240-248 [Article in Spanish].
30.
Saggese GB, Giampiero I, Federico, G, et al. Effects of growth hormone on phosphocalcium homeostasis and bone metabolism. Hormone Res 1995; 44: 55-63.
31.
Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the kidney disease: improving global outcomes 2017 clinical practice guideline update. Ann Int Med 2018; 168: 422.
32.
McAlister L, Pugh P, Greenbaum L, et al. The dietary management of calcium and phosphate in children with CKD stages 2–5 and on dialysis – clinical practice recommendation from the pediatric renal nutrition taskforce. Pediatr Nephrol 2020; 35: 501-518.
33.
Bacchetta J, Bernardor J, Garnier C, et al. Hyperphosphatemia and chronic kidney disease: a major daily concern both in adults and in children. Calcif Tissue Int 2021; 108: 116-127.
34.
Shroff R, Long DA, Shanahan C. Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 2013; 24: 179-189.
35.
Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in children. Pediatr Nephrol 2008; 23: 195-207.
36.
Caputo M, Pigni S, Agosti E, et al. Regulation of GH and GH signaling by nutrients. Cells 2021; 10: 1376.
37.
Kamenický P, Mazziotti G, Lombès M, et al. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocrin Rev 2014; 35: 234-281.
38.
Pańczyk-Tomaszewska M, Ziółkowska, H, Dębiński, A, et al. Vitamin D metabolite requirements in dialysed children receiving recombinant human growth hormone. Nephrol Dial Transplant 2000; 15: 375-378.
39.
Klaus G, Watson A, Edefonti A, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 2006; 21: 151-159.
40.
Bacchetta J. Treatment of hyperphosphatemia: the dangers of high PTH levels. Pediatr Nephrol 2020; 35: 493-500.
41.
Johnson VL, Wang J, Kaskel FJ, et al. Changes in body composition of children with chronic renal failure on growth hormone. Pediatr Nephrol 2000; 14: 695-700.
42.
Hogler W, Briody J, Moore B, et al. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency. Bone 2005; 37: 642-650.
43.
Claramunt D, Gil-Peña H, Fuente R, et al. Effects of growth hormone treatment on growth plate, bone, and mineral metabolism of young rats with uremia induced by adenine. Pediatr Res 2017; 82: 148-154.
44.
Troib A, Guterman M, Rabkin R, et al. Endurance exercise and growth hormone improve bone formation in young and growth- retarded chronic kidney disease rats. Nephrol Dial Transplant 2016; 31: 1270-1279.
45.
Van der Sluis IM, Boot AM, Nauta J, et al. Bone density and body composition in chronic renal failure: effects of growth hormone treatment. Pediatr Nephrol 2000; 15: 221-228.
46.
Iseri K, Dai L, Chen Z, et al. Bone mineral density and mortality in end-stage renal disease patients. Clin Kidney J 2020; 13: 307-321.
47.
Nawrot-Wawrzyniak K, Misof BM, Roschger P, et al. Changes in bone matrix mineralization after growth hormone treatment in children and adolescents with chronic kidney failure treated by dialysis: a paired biopsy study. Am J Kidney Dis 2013; 61: 767-777.
48.
Mehls O, Lindberg A, Haffner D, et al. Long-term growth hormone treatment in short children with CKD does not accelerate decline of renal function: results from the KIGS registry and ESCAPE trial. Pediatr Nephrol 2015; 30: 2145-2151.
49.
Wühl E, Picca S, Litwin M, et al. Strict blood-pressure control and progression of renal failure in children. N En J Med 2009; 361: 1639-1650.
50.
Kamath N, Iyengar A, George N, et al. Risk factors and rate of progression of CKD in children. Kidney Int Rep 2019; 4: 1472-1477.
51.
Boot AM, Nauta J, de Jong MC, et al. Bone mineral density, bone metabolism and body composition of children with chronic renal failure, with and without growth hormone treatment. Clin Endocrinol (Oxf) 1998; 49: 665-672.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
